Publication:
Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

Simple item page
dc.conference.dateMAR 30-APR 02, 2022
dc.conference.titleEuropean Lung Cancer Congress (ELCC)
dc.contributor.authorCasarrubios, M.
dc.contributor.authorCruz-Bermudez, A.
dc.contributor.authorSierra-Rodero, B.
dc.contributor.authorNadal, E.
dc.contributor.authorInsa-Molla, M. A.
dc.contributor.authorGarcia-Campelo, M. R.
dc.contributor.authorGarcia-Benito, C.
dc.contributor.authorDomine-Gomez, M.
dc.contributor.authorMajem-Tarruella, M.
dc.contributor.authorRodriguez-Abreu, D.
dc.contributor.authorMartinez, A.
dc.contributor.authorDe-Castro-Carpeno, J.
dc.contributor.authorCobo-Dols, M.
dc.contributor.authorLopez-Vivanco, G.
dc.contributor.authorVinolas-Segarra, N.
dc.contributor.authorBarneto-Aranda, I. C.
dc.contributor.authorViteri, S.
dc.contributor.authorMassuti-Sureda, B.
dc.contributor.authorProvencio-Pulla, M.
dc.contributor.authoraffiliation[Casarrubios, M.] Hosp Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Med Oncol, Majadahonda, Spain
dc.contributor.authoraffiliation[Cruz-Bermudez, A.] Hosp Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Med Oncol, Majadahonda, Spain
dc.contributor.authoraffiliation[Sierra-Rodero, B.] Hosp Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Med Oncol, Majadahonda, Spain
dc.contributor.authoraffiliation[Provencio Pulla, M.] Hosp Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Med Oncol, Majadahonda, Spain
dc.contributor.authoraffiliation[Nadal, E.] ICO Inst Catala Oncol IHosp Hosp Duran Reynals, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Insa Molla, M. A.] Hosp Clin Univ Valencia, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Garcia Campelo, M. R.] Univ Hosp Coruna, CHUAC, Coruna, Spain
dc.contributor.authoraffiliation[Garcia Benito, C.] Hosp Univ Alvaro Cunqueiro, Dept Oncol, Vigo, Spain
dc.contributor.authoraffiliation[Domine Gomez, M.] IIS Hosp Fdn Jimenez Diaz, Madrid, Spain
dc.contributor.authoraffiliation[Majem Tarruella, M.] Hosp Santa Creu & Sant Pau, Barcelona, Spain
dc.contributor.authoraffiliation[Rodriguez-Abreu, D.] Univ Insular Gran Canaria, Hosp Univ Insular Gran Canaria, Dept Med Oncol, Las Palmas Gran Canaria, Spain
dc.contributor.authoraffiliation[Martinez, A.] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[De Castro Carpeno, J.] Hosp Univ La Paz, Departimento Oncol Med, Madrid, Spain
dc.contributor.authoraffiliation[Cobo Dols, M.] Hosp Reg Malaga, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Lopez Vivanco, G.] Hosp Cruces, Baracaldo, Spain
dc.contributor.authoraffiliation[Vinolas Segarra, N.] Hosp Clin Prov Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Barneto Aranda, I. C.] Hosp Univ Reina Sofia, Cordoba, Spain
dc.contributor.authoraffiliation[Viteri, S.] Hosp Univ Quiron Dexeusm Grupo Quiron Salud, Inst Oncol Dr Rosell, Barcelona, Spain
dc.contributor.authoraffiliation[Massuti Sureda, B.] Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain
dc.contributor.funderBristol Myers Squibb
dc.contributor.funder"Instituto de Salud Carlos III'' (ISCIII)
dc.contributor.funderEuropean Regional Development Fund (ERDF)
dc.contributor.funderEuropean Social Fund (ESF)
dc.contributor.funderComunidad de Madrid
dc.contributor.funderMinistry of Science and Innovation
dc.date.accessioned2023-05-03T14:39:32Z
dc.date.available2023-05-03T14:39:32Z
dc.date.issued2022-04-02
dc.description.abstractBackground: Neoadjuvant chemoimmunotherapy (CI) for NSCLC is a promising strategy that yields high rates of complete pathological responses (CPR) that are associated with long-term survival. We analyzed the tumor microenvironment by using gene expression profiling in patients from NADIM trial to identify biomarkers predicting CPR. Methods: RNAs extracted from whole sections of pre-treatment tumors of 14 patients enrolled in NADIM trial (NCT03081689) were sequenced using the Oncomine Immune Response Research Assay panel. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and Gene Set Enrichment Analysis (GSEA). CIBERSORTx was used to estimate the proportions of immune cells subtypes. Results were correlated with pathological response groups: complete (CPR, n¼9) and non-complete (non-CPR, n¼5) responders.
dc.identifier.citationCasarrubios, M., Cruz-Bermudez, A., Sierra-Rodero, B., Nadal, E., Molla, M. I., Campelo, G., et al. Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy. Annals Of Oncology, 33, S105. https://doi.org/10.1016/j.annonc.2022.02.189
dc.identifier.doi10.1016/j.annonc.2022.02.189
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422003052/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21894
dc.identifier.wosID778453100159
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Regional de Málaga
dc.page.number1
dc.provenanceRealizada la curación de contenido 08/04/2025
dc.publisherElsevier
dc.rights.accessRightsRestricted Access
dc.subjectTumor Microenvironment
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectGene Expression Profiling
dc.subject.decsReanimación Cardiopulmonar
dc.subject.decsMicroambiente Tumoral
dc.subject.decsInmunidad
dc.subject.decsPerfilación de la Expresión Génica
dc.subject.meshHumans
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshBiomarkers
dc.subject.meshImmunity
dc.titleImmune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía